Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982;13(Suppl 2):245S–257S. doi: 10.1111/j.1365-2125.1982.tb01922.x

How intrinsic sympathomimetic activity modulates the haemodynamic responses to β-adrenoceptor antagonists

A clue to the nature of their antihypertensive mechanism

A J Man in 'T Veld, M A D H Schalekamp
PMCID: PMC1402134  PMID: 6125175

Abstract

1 A survey has been made of the literature on acute and long-term haemodynamic effects of ten different β-adrenoceptor antagonists.

The β-adrenoceptor blockers are: pindolol, practolol, alprenolol, oxprenolol, acebutolol, penbutolol, metoprolol, atenolol, propranolol and timolol. The total numbers of patients included in this review are 396 patients in 41 acute studies and 410 patients in 36 long-term studies.

2 The effects of β-adrenoceptor blockers on the concentrations of plasma noradrenaline have also been reviewed. Ten studies including 110 patients on non-ISA-β-adrenoceptor blockers and eight studies including 116 patients on pindolol are presented.

3 In the acute studies (i.e. 15-90 min) arterial pressure was lowered by 1-7% and in the long-term studies (i.e. 3 days-5 years) by 6-17%.

4 The degree of cardio-depression induced by the various β-adrenoceptor blockers was inversely correlated with their pharmacologically defined quantity of intrinsic sympathomimetic activity (ISA) both in acute and in long-term studies.

5 In the acute studies the increments in peripheral vascular resistance were directly correlated with the degree of cardio-depression. This suggests that a fall in arterial pressure immediately after administration of a β-adrenoceptor blocker is prevented by increased vasoconstrictor nerve activity mediated through the arterial baroreflex.

6 The compensatory response of vascular resistance to cardio-depression was similar for β1-selective and non-selective blockers, thereby indicating that extra-junctional vascular β-receptors are relatively unimportant for maintaining basal vascular tone.

7 In the long-term studies the correlation between changes in cardiac output and changes in vascular resistance was shifted to a lower level of vascular resistance. This means that the onset of blood pressure reduction during β-adrenoceptor blockade was associated with a fall in vascular resistance at any level of cardiac output. Thus vascular resistance was higher during treatment with a non-ISA-β-adrenoceptor blocker than during treatment with an ISA-β-adrenoceptor blocker.

8 The level of vascular resistance ultimately attained during treatment with the various β-adrenoceptor blockers appears to be inversely related to their effects on plasma renin activity.

9 The concentration of noradrenaline in plasma rose by approximately 30% during treatment with non-ISA-β-adrenoceptor blockers and fell by more than 30% after pindolol.

10 There is evidence that under propranolol, which reduces cardiac output and hepatic blood flow, the plasma noradrenaline clearance is diminished. Since noradrenaline is mainly cleared from the circulation by the lungs and by the liver, and since pindolol has no effect on cardiac output and hepatic blood flow, one may expect the plasma noradrenaline clearance not to be diminished by pindolol.

11 The reported effects of β-adrenoceptor blockers on plasma noradrenaline may indicate that the release of neurotransmitter is diminished, but in the case of non-ISA-β-adrenoceptor blockers this effect is not reflected by a decreased concentration of noradrenaline in plasma, because its clearance is also reduced.

12 The hypotensive effect of β-adrenoceptor blockers appears to be independent of blockade of postjunctional cardiac-β-receptors, juxtaglomerular-β-receptors and extrajunctional vascular β-receptors. This indicates that blockade of β-receptors at other sites (i.e. centrally and/or prejunctionally) is more important.

Full text

PDF
245S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adolfsson L., Sonnhag C. Hemodynamic effects of two cardioselective beta-adrenoceptive antagonists, metoprolol and H 87/07, in coronary insufficiency. Scand J Clin Lab Invest. 1976 Dec;36(8):755–761. doi: 10.3109/00365517609081934. [DOI] [PubMed] [Google Scholar]
  2. Amery A., Billiet L., Boel A., Fagard R., Reybrouck T., Willems J. Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients. Am Heart J. 1976 May;91(5):634–642. doi: 10.1016/s0002-8703(76)80149-4. [DOI] [PubMed] [Google Scholar]
  3. Anavekar S. N., Louis W. J., Morgan T. O., Doyle A. E., Johnston C. I. The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol. 1975 May-Jun;2(3):203–212. doi: 10.1111/j.1440-1681.1975.tb03026.x. [DOI] [PubMed] [Google Scholar]
  4. Andersson O., Berglund G. Antihypertensive effect of beta-1 receptor blockade and beta-2-receptor stimulation in essential hypertension. Acta Med Scand. 1975 Jun;197(6):495–496. doi: 10.1111/j.0954-6820.1975.tb04958.x. [DOI] [PubMed] [Google Scholar]
  5. Aronow W. S., Ferlinz J., Del Vicario M., Moorthy K., King J., Cassidy J. Effect of timolol versus propranolol on hypertension and hemodynamics. Circulation. 1976 Jul;54(1):47–51. doi: 10.1161/01.cir.54.1.47. [DOI] [PubMed] [Google Scholar]
  6. Aström H., Jonsson B. Haemodynamic effects of different beta blockers in angina pectoris. Scott Med J. 1977 Jan;22(1):64–68. doi: 10.1177/003693307702200116. [DOI] [PubMed] [Google Scholar]
  7. Atterhög J. H., Dunér H., Pernow B. Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976 May 31;60(6):872–876. doi: 10.1016/0002-9343(76)90907-4. [DOI] [PubMed] [Google Scholar]
  8. BLACK J. W., STEPHENSON J. S. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet. 1962 Aug 18;2(7251):311–314. doi: 10.1016/s0140-6736(62)90103-4. [DOI] [PubMed] [Google Scholar]
  9. Bannan L. T., Beevers D. G. Emergency treatment of high blood pressure with oral atenolol. Br Med J (Clin Res Ed) 1981 May 30;282(6278):1757–1758. doi: 10.1136/bmj.282.6278.1757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Berthelsen S., Pettinger W. A. A functional basis for classification of alpha-adrenergic receptors. Life Sci. 1977 Sep 1;21(5):595–606. doi: 10.1016/0024-3205(77)90066-2. [DOI] [PubMed] [Google Scholar]
  11. Birkenhäger W. H., Krauss X. H., Schalekamp M. A., Kolsters G., Kroon B. J. Antihypertensive effects of propranolol. Observations on predictability. Folia Med Neerl. 1971;14(2):67–71. [PubMed] [Google Scholar]
  12. Bodem G., Brammell H. L., Weil J. V., Chidsey C. A. Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol. J Clin Invest. 1973 Apr;52(4):747–754. doi: 10.1172/JCI107237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Brecht H. M., Banthien F., Ernst W., Schoeppe W. Increased plasma noradrenaline concentrations in essential hypertension and their decrease after long-term treatment with a beta-receptor-blocking agent (prindolol). Clin Sci Mol Med Suppl. 1976 Dec;3:485S–488S. doi: 10.1042/cs051485s. [DOI] [PubMed] [Google Scholar]
  14. Brecht H. M., Banthien F., Schoeppe W. Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension. Klin Wochenschr. 1976 Nov 15;54(22):1095–1105. doi: 10.1007/BF01469113. [DOI] [PubMed] [Google Scholar]
  15. Bühler F. R., Laragh J. H., Baer L., Vaughan E. D., Jr, Brunner H. R. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972 Dec 14;287(24):1209–1214. doi: 10.1056/NEJM197212142872401. [DOI] [PubMed] [Google Scholar]
  16. Bühler F. R., Laragh J. H., Vaughan E. D., Jr, Brunner H. R., Gavras H., Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol. 1973 Sep 20;32(4):511–522. doi: 10.1016/s0002-9149(73)80043-8. [DOI] [PubMed] [Google Scholar]
  17. Castenfors J., Johnsson H., Orö L. Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients. Acta Med Scand. 1973 Mar;193(3):189–195. doi: 10.1111/j.0954-6820.1973.tb10560.x. [DOI] [PubMed] [Google Scholar]
  18. Chew C. Y., Collett J., Shah P. K., Singh B. N. Hemodynamic effects of intravenous timolol in coronary artery disease. Clin Pharmacol Ther. 1979 Sep;26(3):330–338. doi: 10.1002/cpt1979263330. [DOI] [PubMed] [Google Scholar]
  19. Cryer P. E., Rizza R. A., Haymond M. W., Gerich J. E. Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism. 1980 Nov;29(11 Suppl 1):1114–1118. doi: 10.1016/0026-0495(80)90019-0. [DOI] [PubMed] [Google Scholar]
  20. Distler A., Keim H. J., Cordes U., Philipp T., Wolff H. P. Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension. Am J Med. 1978 Mar;64(3):446–451. doi: 10.1016/0002-9343(78)90231-0. [DOI] [PubMed] [Google Scholar]
  21. Doyle A. E. Use of beta-adrenoreceptor blocking drugs in hypertension. Drugs. 1974;8(6):422–431. doi: 10.2165/00003495-197408060-00006. [DOI] [PubMed] [Google Scholar]
  22. Dreslinski G. R., Aristimuno G. G., Messerli F. H., Suarez D. H., Frohlich E. D. Effects of beta blockade with acebutolol on hypertension, hemodynamics, and fluid volume. Clin Pharmacol Ther. 1979 Nov;26(5):562–565. doi: 10.1002/cpt1979265562. [DOI] [PubMed] [Google Scholar]
  23. Esler M. D., Nestel P. J. Evaluation of practolol in hypertension. Effects on sympathetic nervous system and renin responsiveness. Br Heart J. 1973 May;35(5):469–474. doi: 10.1136/hrt.35.5.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Esler M., Jackman G., Leonard P., Skews H., Bobik A., Jennings G. Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. Br J Clin Pharmacol. 1981 Sep;12(3):375–380. doi: 10.1111/j.1365-2125.1981.tb01229.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Fagard R., Amery A., Deplaen J. F., Lijnen P., Missotten A. Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol. Clin Sci Mol Med Suppl. 1976 Dec;3:215s–217s. doi: 10.1042/cs051215s. [DOI] [PubMed] [Google Scholar]
  26. Fitzgerald J. D., Ruffin R., Smedstad K. G., Roberts R., McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol. 1978 May 17;13(2):81–89. doi: 10.1007/BF00609750. [DOI] [PubMed] [Google Scholar]
  27. Forsberg S. A., Johnsson G. Hemodynamic effects of propranolol and H 56-28 in man--comparative study of two beta-adrenergic receptor antagonists. Acta Pharmacol Toxicol (Copenh) 1967;25:75–83. doi: 10.1111/j.1600-0773.1967.tb02998.x. [DOI] [PubMed] [Google Scholar]
  28. Franz I. W., Lohmann F. W., Koch G. Differential effects of long-term cardioselective and nonselective beta-receptor blockade on plasma catecholamines during and after physical exercise in hypertensive patients. J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):35–44. doi: 10.1097/00005344-198001000-00005. [DOI] [PubMed] [Google Scholar]
  29. Frisk-Holmberg M., Jorfeldt L., Juhlin-Dannfeldt A. Influence of alprenolol on hemodynamic and metabolic responses to prolonged exercise in subjects with hypertension. Clin Pharmacol Ther. 1977 Jun;21(6):675–684. doi: 10.1002/cpt1977216675. [DOI] [PubMed] [Google Scholar]
  30. Gavras I., Gavras H., Tifft C. P., Kershaw G. R., Bresnahan M. Effect of pindolol on blood pressure, plasma renin activity, and catecholamines in hypertensive patients. J Clin Pharmacol. 1981 Feb-Mar;21(2):79–83. doi: 10.1002/j.1552-4604.1981.tb01753.x. [DOI] [PubMed] [Google Scholar]
  31. Gordon R. D. Effects of beta-adrenoreceptor blocking drugs on plasma volume. Renin and aldosterone as components of their antihypertensive action. Drugs. 1976;11(Suppl 1):156–163. doi: 10.2165/00003495-197600111-00032. [DOI] [PubMed] [Google Scholar]
  32. Hansson B. G., Hökfelt B. Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol. 1975 Oct 10;9(1):9–19. doi: 10.1007/BF00613424. [DOI] [PubMed] [Google Scholar]
  33. Hansson L. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand Suppl. 1973;550:1–40. [PubMed] [Google Scholar]
  34. Hansson L., Malmcrona R., Olander R., Rosenhall L., Westerlund A., Aberg H., Hood B. Propranolol in hypertension. Report on 158 patients treated up to one year. Klin Wochenschr. 1972 Apr 1;50(7):364–369. doi: 10.1007/BF01486832. [DOI] [PubMed] [Google Scholar]
  35. Hansson L., Zweifler A. J., Julius S., Hunyor S. N. Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension. Acta Med Scand. 1974 Jul-Aug;196(1-2):27–34. doi: 10.1111/j.0954-6820.1974.tb00962.x. [DOI] [PubMed] [Google Scholar]
  36. Hartling O. J., Noer I., Svendsen T. L., Clausen J. P., Trap-Jensen J. Selective and non-selective beta-adrenoreceptor blockade in the human forearm. Clin Sci (Lond) 1980 Apr;58(4):279–286. doi: 10.1042/cs0580279. [DOI] [PubMed] [Google Scholar]
  37. Ireland M. A., Littler W. A. The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients. Br J Clin Pharmacol. 1981 Sep;12(3):363–368. doi: 10.1111/j.1365-2125.1981.tb01227.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Isbary J., Greding H., Nechwatal W., König E. Hämodynamische Veränderungen bei Hypertonikern nach beta-Sympathikolyse mit Propranolol und Metoprolol. Z Kardiol. 1978 Dec;67(12):857–862. [PubMed] [Google Scholar]
  39. Jensen H. A., Rasmussen K., Mosbaek N. Clinical and haemodynamic study of atenolol (Tenormin) in essential hypertension. Clin Sci Mol Med Suppl. 1976 Dec;3:525s–526s. doi: 10.1042/cs051525s. [DOI] [PubMed] [Google Scholar]
  40. Kirsten R., Heintz B., Böhmer D., Nelson K., Roth S., Welzel D. Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity. Br J Clin Pharmacol. 1982;13(Suppl 2):397S–406S. doi: 10.1111/j.1365-2125.1982.tb01947.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Klein W. W., Brandt D., Fluch N., Goebel R., Holzer H., Pöch G. Hämodynamische Langzeiteffekte eines Beta-Rezeptorenblockers (Pindolol) bei primärer arterieller Hypertonie. Adv Clin Pharmacol. 1976;11:79–85. [PubMed] [Google Scholar]
  42. Krediet R. T., Dunning A. J. Baroreflex sensitivity in hypertension during beta-adrenergic blockade. Br Heart J. 1979 Jan;41(1):106–110. doi: 10.1136/hrt.41.1.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Lang E., Holtmann W. Veränderungen der Hämodynamik unter dem Einfluss der beta-Sympathikolyse bei zwei verschiedenen Substanzen unterschiedlichen pharmakodynamischen Prinzips. Arzneimittelforschung. 1974 Sep;24(9):1330–1335. [PubMed] [Google Scholar]
  44. Lang R., Maxrath A., Laaser U., Meurer K. A., Kaufmann W. Zur Bedeutung einer Anderung der Gesamt-Bilanz von Natrium und Noradrenalin bei essentieller Hypertonie. Klin Wochenschr. 1978 Nov 15;56(22):1097–1108. doi: 10.1007/BF01477131. [DOI] [PubMed] [Google Scholar]
  45. Langer S. Z. Sixth gaddum memorial lecture, National Institute for Medical Research, Mill Hill, January 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol. 1977 Aug;60(4):481–497. doi: 10.1111/j.1476-5381.1977.tb07526.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Leonetti G., Terzoli L., Bianchini C., Sala C., Zanchetti A. Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration. Eur J Clin Pharmacol. 1980 Nov;18(5):365–374. doi: 10.1007/BF00636787. [DOI] [PubMed] [Google Scholar]
  47. Lewis B. S., Bakst A., Mitha A. S., Purdon K., Gotsman M. S. Haemodynamic effects of a new beta-blocking agent 'Sectral' (M & B 17803A). Br Heart J. 1973 Jul;35(7):743–751. doi: 10.1136/hrt.35.7.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Lewis B. S., Mitha A. S., Bakst A., Purdon K., Gotsman M. S. Haemodynamic effects of beta blockade in hypertrophic cardiomyopathy using Sectral (acebutolol; M and B 17803A). Cardiovasc Res. 1974 Mar;8(2):249–262. doi: 10.1093/cvr/8.2.249. [DOI] [PubMed] [Google Scholar]
  49. Lewis M. J. Effect of acute and chronic treatment with practolol on cardiovascular responses in the pithed rat. J Pharm Pharmacol. 1974 Oct;26(10):783–788. doi: 10.1111/j.2042-7158.1974.tb09174.x. [DOI] [PubMed] [Google Scholar]
  50. Lijnen P. J., Amery A. K., Fagard R. H., Reybrouck T. M., Moerman E. J., De Schaepdryver A. F. The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise. Br J Clin Pharmacol. 1979 Feb;7(2):175–181. doi: 10.1111/j.1365-2125.1979.tb00918.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Ljung B., Ablad B., Dahlöf C., Henning M., Hultberg E. Impaired vasoconstrictor nerve function in spontaneously hypertensive rats after long-term treatment with propranolol and metroprolol. Blood Vessels. 1975;12(5):311–315. doi: 10.1159/000158067. [DOI] [PubMed] [Google Scholar]
  52. Lund-Johansen P. Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br J Clin Pharmacol. 1979;8(Suppl 2):107S–111S. [PMC free article] [PubMed] [Google Scholar]
  53. Lund-Johansen P. Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. Br J Clin Pharmacol. 1976 Jun;3(3):445–451. doi: 10.1111/j.1365-2125.1976.tb00620.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Lund-Johansen P. Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol. J Cardiovasc Pharmacol. 1979 Sep-Oct;1(5):487–495. doi: 10.1097/00005344-197909000-00001. [DOI] [PubMed] [Google Scholar]
  55. Lund-Johansen P. Hemodynamic long-term effects of timolol at rest and during exercise in essential hypertension. Acta Med Scand. 1976;199(4):263–267. doi: 10.1111/j.0954-6820.1976.tb06730.x. [DOI] [PubMed] [Google Scholar]
  56. Lund-Johansen P. Long-term hemodynamic effects of penbutolol at rest and during exercise in essential hypertension. Eur J Clin Pharmacol. 1979 Sep;16(3):149–153. doi: 10.1007/BF00562054. [DOI] [PubMed] [Google Scholar]
  57. Lund-Johansen P., Ohm O. J. Haemodynamic long-term effects of beta-receptor-blocking agents in hypertension: a comparison between alprenolol, atenolol, metoprolol and timolol. Clin Sci Mol Med Suppl. 1976 Dec;3:481S–483S. doi: 10.1042/cs051481s. [DOI] [PubMed] [Google Scholar]
  58. Lund-Johansen P., Ohm O. J. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension. Br J Clin Pharmacol. 1977 Apr;4(2):147–151. doi: 10.1111/j.1365-2125.1977.tb00686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Lund-Larsen G., Sivertssen E. Hemodynamic effects of propranolol (Inderal) and H 56-28 (Aptin) in patients with acute myocardial infarction. A comparative study. Acta Med Scand. 1969 Sep;186(3):187–191. [PubMed] [Google Scholar]
  60. Lysbo Svendsen T., Trap-Jensen J., Bliddal J., Hartling O., McNair A. Acute hemodynamic effects of five beta-adrenoceptor blocking agents in man: the significance of selectivity and intrinsic sympathomimetic activity. Acta Med Scand Suppl. 1979;625:26–30. doi: 10.1111/j.0954-6820.1979.tb00736.x. [DOI] [PubMed] [Google Scholar]
  61. Majewski H., McCulloch M. W., Rand M. J., Story D. F. Adrenaline activation of prejunctional beta-adrenoceptors in guinea-pig atria. Br J Pharmacol. 1980;71(2):435–444. doi: 10.1111/j.1476-5381.1980.tb10956.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Majewski H., Tung L. H., Rand M. J. Adrenaline-induced hypertension in rats. J Cardiovasc Pharmacol. 1981 Jan-Feb;3(1):179–185. doi: 10.1097/00005344-198101000-00016. [DOI] [PubMed] [Google Scholar]
  63. Majid P. A., Sharma B., Saxton C., Stoker J. B., Taylor S. H. Haemodynamic effects of oxprenolol in hypertensive patients. Postgrad Med J. 1970 Nov;(Suppl):67–72. [PubMed] [Google Scholar]
  64. Man in 't Veld A. J., Wenting G. J., Boomsma F., Verhoeven R. P., Schalekamp M. A. Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. Br J Clin Pharmacol. 1980 Jun;9(6):547–551. doi: 10.1111/j.1365-2125.1980.tb01079.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Man in 't Veld A. J., Wenting G. J., Verhoeven R. P., Schalekamp M. A. Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. Clin Sci Mol Med Suppl. 1978 Dec;4:329s–332s. doi: 10.1042/cs055329s. [DOI] [PubMed] [Google Scholar]
  66. Mason J. W., Specter M. J., Ingels N. B., Daughters G. T., Ferris A. C., Alderman E. L. Haemodynamic effects of acebutolol. Br Heart J. 1978 Jan;40(1):29–34. doi: 10.1136/hrt.40.1.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Mazurkiewicz-Kwilecki I. M., Romagnoli A. Cardiac catecholamine levels and blood pressure after chronic treatment with beta-adrenergic blocking agents. J Pharm Pharmacol. 1970 Mar;22(3):235–237. doi: 10.1111/j.2042-7158.1970.tb08507.x. [DOI] [PubMed] [Google Scholar]
  68. Morgan T. O., Roberts R., Carney S. L., Louis W. J., Doyle A. E. Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol. 1975 Apr;2(2):159–164. doi: 10.1111/j.1365-2125.1975.tb01571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Neil-Dwyer G., Bartlett J., McAinsh J., Cruickshank J. M. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol. 1981 Jun;11(6):549–553. doi: 10.1111/j.1365-2125.1981.tb01169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. PRICHARD B. N. HYPOTENSIVE ACTION OF PRONETHALOL. Br Med J. 1964 May 9;1(5392):1227–1228. doi: 10.1136/bmj.1.5392.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Petrie J. C., Galloway D. B., Webster J., Simpson W. T., Lewis J. A. Atenolol and bendrofluazide in hypertension. Br Med J. 1975 Oct 18;4(5989):133–135. doi: 10.1136/bmj.4.5989.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Pickering T. G., Gribbin B., Petersen E. S., Cunningham D. J., Sleight P. Effects of autonomic blockade on the baroreflex in man at rest and during exercise. Circ Res. 1972 Feb;30(2):177–185. doi: 10.1161/01.res.30.2.177. [DOI] [PubMed] [Google Scholar]
  73. Prichard B. N. The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol. 1978 May;5(5):379–399. doi: 10.1111/j.1365-2125.1978.tb01644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Rahn K. H., Gierlichs H. W., Planz G., Planz R., Schols M., Stephany W. Studies on the effects of propanolol on plasma catecholamine levels in patients with essential hypertension. Eur J Clin Invest. 1978 Jun;8(3):143–148. doi: 10.1111/j.1365-2362.1978.tb00827.x. [DOI] [PubMed] [Google Scholar]
  75. Raine A. E., Chubb I. W. Long term beta-adrenergic blockade reduces tyrosine hydroxylase and dopamine beta-hydroxylase activities in sympathetic ganglia. Nature. 1977 May 19;267(5608):265–267. doi: 10.1038/267265a0. [DOI] [PubMed] [Google Scholar]
  76. Raine A. E., Pickering T. G. Cardiovascular and sympathetic response to exercise after long-term beta-adrenergic blockade. Br Med J. 1977 Jul 9;2(6079):90–92. doi: 10.1136/bmj.2.6079.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Reale A., Nigri A., Gioffrè P. A., Motolese M. Acute influence of different beta-blocking agents upon left heart hemodynamics at rest and during exercise in patients with coronary artery disease. Eur J Cardiol. 1979 Feb;9(2):101–109. [PubMed] [Google Scholar]
  78. Sannerstedt R. Hemodynamic effects of adrenergic beta-receptor blocking agents. Adv Clin Pharmacol. 1976;11:70–78. [PubMed] [Google Scholar]
  79. Sannerstedt R., Wasir H. Acute haemodynamic effects of metoprolol in hypertensive patients. Br J Clin Pharmacol. 1977 Feb;4(1):23–26. doi: 10.1111/j.1365-2125.1977.tb00661.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Simon G., Kiowski W., Julius S. Effect of beta adrenoceptor antagonists on baroreceptor reflex sensitivity in hypertension. Clin Pharmacol Ther. 1977 Sep;22(3):293–298. doi: 10.1002/cpt1977223293. [DOI] [PubMed] [Google Scholar]
  81. Simpson F. O. Beta-adrenergic receptor blocking drugs in hypertension. Drugs. 1974;7(1):85–105. doi: 10.2165/00003495-197407010-00006. [DOI] [PubMed] [Google Scholar]
  82. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol. 1977;77:1–124. doi: 10.1007/BFb0050157. [DOI] [PubMed] [Google Scholar]
  83. Stenberg J., Wasir H., Amery A., Sannerstedt R., Werkö L. Comparative hemodynamic studies in man of adrenergic bepta-1-receptors agents without (h 93/26 equal to metoprolol) or with (h 87/07) intrinsic sympathicomimetic activity. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):76–84. doi: 10.1111/j.1600-0773.1975.tb03324.x. [DOI] [PubMed] [Google Scholar]
  84. Stjärne L., Brundin J. Beta2-adrenoceptors facilitating noradrenaline secretion from human vasoconstrictor nerves. Acta Physiol Scand. 1976 Mar;97(1):88–93. doi: 10.1111/j.1748-1716.1976.tb10238.x. [DOI] [PubMed] [Google Scholar]
  85. Stokes G. S., Weber M. A., Thornell I. R. Beta-blockers and plasma renin activity in hypertension. Br Med J. 1974 Jan 12;1(5897):60–62. doi: 10.1136/bmj.1.5897.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Struyker-Boudier H. A., Smits J. F., Van Essen H. The role of the baroreceptor reflex in the cardiovascular effects of propranolol in the conscious spontaneously hypertensive rat. Clin Sci (Lond) 1979 Feb;56(2):163–167. doi: 10.1042/cs0560163. [DOI] [PubMed] [Google Scholar]
  87. Stumpe K. O., Kolloch R., Vetter H., Gramann W., Krück F., Ressel C., Higuchi M. Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure. Am J Med. 1976 May 31;60(6):853–865. doi: 10.1016/0002-9343(76)90905-0. [DOI] [PubMed] [Google Scholar]
  88. Svendsen T. L., Carlsen J. E., Hartling O., McNair A., Trap-Jensen J. A comparison of the acute haemodynamic effects of propranolol and pindolol at rest and during supine exercise in man. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):465s–468s. doi: 10.1042/cs059465s. [DOI] [PubMed] [Google Scholar]
  89. Svendsen T. L., Hartling O., Trap-Jensen J. Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers. Eur J Clin Pharmacol. 1979 May 21;15(4):223–228. doi: 10.1007/BF00618509. [DOI] [PubMed] [Google Scholar]
  90. Svendsen T. L., Tangø M., Waldorff S., Steiness E., Trap-Jensen J. Effects of propranolol and pindolol on plasma lignocaine clearance in man. Br J Clin Pharmacol. 1982;13(Suppl 2):223S–226S. doi: 10.1111/j.1365-2125.1982.tb01915.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Tarazi R. C., Dustan H. P. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol. 1972 May;29(5):633–640. doi: 10.1016/0002-9149(72)90164-6. [DOI] [PubMed] [Google Scholar]
  92. Undeutsch K., Sieberth H. G., Meurer K. A. Beeinflussung der renalen Hypertonie durch den Beta-Receptorenblocker Prindolol. Klin Wochenschr. 1976 Nov 15;54(22):1077–1084. doi: 10.1007/BF01469111. [DOI] [PubMed] [Google Scholar]
  93. Vandenburg M. J., Conlon C., Ledingham J. M. A comparison of the effects of propranolol and oxprenolol on forearm blood flow and skin temperature. Br J Clin Pharmacol. 1981 May;11(5):485–490. doi: 10.1111/j.1365-2125.1981.tb01154.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Vandongen R., Davidson L., Beilin L. J., Barden A. E. Effect of beta-adrenergic receptor blockade with propranolol on the response of plasma catecholamines and renin activity to upright tilting in normal subjects. Br J Clin Pharmacol. 1981 Sep;12(3):369–374. doi: 10.1111/j.1365-2125.1981.tb01228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Wale J., Pun L. Q., Rand M. J. The effects of ICI 50172, propranolol, pronethalol and MJ 1999 on beta-receptors. Eur J Pharmacol. 1969 Oct;8(1):25–35. doi: 10.1016/0014-2999(69)90125-3. [DOI] [PubMed] [Google Scholar]
  96. Walter I., Kusus T., Wagner K., Lydtin H. Die Wirkung eines beta-Receptorenblockers auf das Herzminutenvolumen--Untersuchungen bei essentieller Hypertonie und hyperkinetischem Herzsyndrom unter Berücksichtigung der Plasma-Adrenalin- und -Noradrenalinspiegel. Verh Dtsch Ges Inn Med. 1973;79:1010–1013. [PubMed] [Google Scholar]
  97. Wasserman A. J., Proctor J. D., Allen F. J., Kemp V. E., Jr Human cardiovascular effects of alprenolol, a beta-adrenergic blocker: hemodynamic, antiarrhythmic, and antianginal. J Clin Pharmacol J New Drugs. 1970 Jan-Feb;10(1):37–49. [PubMed] [Google Scholar]
  98. Weber M. A., Stokes G. S., Gain J. M. Comparison of the effects on renin release of beta adrenergic antagonists with differing properties. J Clin Invest. 1974 Dec;54(6):1413–1419. doi: 10.1172/JCI107888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Webster J., Jeffers T. A., Galloway D. B., Petrie J. C., Barker N. P. Atenolol, methyldopa, and chlorthalidone in moderate hypertension. Br Med J. 1977 Jan 8;1(6053):76–78. doi: 10.1136/bmj.1.6053.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Wilcox C. S., Lewis P. S., Peart W. S., Sever P. S., Osikowska B. A., Suddle S. A., Bluhm M. M., Veall N., Lancaster R. Renal function, body fluid volumes, renin, aldosterone, and noradrenaline during treatment of hypertension with pindolol. J Cardiovasc Pharmacol. 1981 May-Jun;3(3):598–611. doi: 10.1097/00005344-198105000-00018. [DOI] [PubMed] [Google Scholar]
  101. Wilson D. F., Watson O. F., Peel J. S., Langley R. B., Turner A. S. Some haemodynamic effects of trasicor (Ciba 39,089-Ba). N Z Med J. 1968 Sep;68(436):145–149. [PubMed] [Google Scholar]
  102. Wing L. M., Reid J. L., Hamilton C. A., Sever P., Davies D. S., Dollery C. T. Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med. 1977 Jul;53(1):45–53. doi: 10.1042/cs0530045. [DOI] [PubMed] [Google Scholar]
  103. Wollam G. L., Cody R. J., Jr, Tarazi R. C., Bravo E. L. Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol. Clin Pharmacol Ther. 1979 Jun;25(6):813–820. doi: 10.1002/cpt1979256813. [DOI] [PubMed] [Google Scholar]
  104. Yamaguchi N., de Champlain J., Nadeau R. A. Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. Circ Res. 1977 Jul;41(1):108–117. doi: 10.1161/01.res.41.1.108. [DOI] [PubMed] [Google Scholar]
  105. de Leeuw P. W., Falke H. E., Kho T. L., Vandongen R., Wester A., Birkenhäger W. H. Effects of beta-adrenergic blockade on diurnal variability of blood pressure and plasma noradrenaline levels. Acta Med Scand. 1977;202(5):389–392. doi: 10.1111/j.0954-6820.1977.tb16849.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES